Akebia Therapeutics (AKBA) Capital Expenditures Growth (3y) (2016 - 2025)
Akebia Therapeutics (AKBA) Capital Expenditures Growth (3y) (2016 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 6.52% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 232.22% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 34.64% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 147.53% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 28.56% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -15.83% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 89.86% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | -61.38% |
| 10 | Akebia Therapeutics | 243.23 Mn | 80.63 Mn | 41.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -45.95% |
| Mar 31, 2022 | -61.04% |
| Mar 31, 2021 | -41.59% |
| Dec 31, 2020 | -11.02% |
| Sep 30, 2020 | -27.56% |
| Jun 30, 2020 | -32.76% |
| Dec 31, 2019 | 66.11% |
| Sep 30, 2019 | 26.28% |
| Jun 30, 2019 | 16.56% |
| Mar 31, 2019 | 160.55% |
| Dec 31, 2018 | 125.90% |
| Sep 30, 2018 | 38.72% |
| Jun 30, 2018 | 85.74% |
| Mar 31, 2018 | 13.96% |
| Dec 31, 2017 | 177.76% |
| Sep 30, 2017 | 152.69% |
| Jun 30, 2017 | 72.17% |
| Mar 31, 2017 | 44.34% |
| Dec 31, 2016 | 54.56% |